- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00972387
Carbohydrate-Protein Supplementation During Endurance Running
April 3, 2018 updated by: Hollie Raynor, The University of Tennessee, Knoxville
"Nutritional Ergogenic Aids: The Effects of Carbohydrate-Protein Supplementation During Endurance Exercise"
The purpose of this study is to assess whether the greater performance benefits from ingesting carbohydrate-protein supplements during endurance running, in comparison to the traditionally used carbohydrate supplement, is attributed to the extra calories contained in the carbohydrate-protein supplement or the presence of protein.
Study Overview
Status
Completed
Conditions
Detailed Description
The purpose of this study is to determine whether the performance benefits from consuming a carbohydrate-protein (CHO-P) supplement, such as Accelerade, during endurance exercise, as opposed to the traditionally used carbohydrate (CHO) supplement, such as Gatorade, are attributed to the extra calories in the CHO-P supplement or the presence of protein alone in comparison to CHO supplements.
Numerous studies comparing CHO and CHO-P supplements on endurance performance have found contradicting results in terms of CHO-P supplementation and performance benefits.
While physiological mechanisms have been proposed as to why the CHO-P supplements elicit greater performance, research has yet to determine why some studies have found this, especially while other studies have found no performance benefits from CHO-P supplementation.
This inconsistency in research may be due to the caloric difference between supplements tested; due to the addition of protein, the CHO-P supplement contains more calories per serving than the CHO supplement.
As a result, this study will be comparing 4 different supplements during endurance exercise, a CHO-P supplement, CHO supplement, a double carbohydrate supplement (CHO-CHO), and a placebo (PLA).
The CHO and CHO-P supplement will be matched for CHO content, whereas the CHO-P and CHO-CHO supplements will be matched for total caloric content.
Participants will be asked to run four 12-mile runs on 4 separate occasions, approximately 7-10 days apart, and will be blinded to supplement content and order of supplement administration among trials.
The 12-mile run will elicit an exercise bout greater than 60 minutes, which is relevant when supplementing exercise with CHO or CHO-P.
Performance will be assessed via time it takes to complete both the 12-mile run and the 1.6 mile maximal effort at the end of the run.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37996
- Health Physical Education and Recreation Building
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Males aged 18-55 years old
- BMI in the healthy range, 18.5-24.9
- Run 45-90+ minutes at least 4 days per week
- Engage in running this frequency and duration for at least 4 weeks prior to the phone screen
- Engage in a run consisting ≥10 miles in length for at least 2-4 occasions per month for at least 2 months prior to the phone screen
- No previous history of heart conditions
- No shortness of breath or chest pain experienced during running or daily activities
- No bone or joint problems experienced during running or daily activities
Exclusion Criteria:
- Females and males under the age of 18 and over the age of 55
- Females are excluded from this study in order to prevent any potential factors associated with the female athlete triad and endurance performance outcomes.
- BMI below 18.5 or greater than 24.9
- Does not meet all other criteria listed (#3-6)
- Allergies to products containing milk, soy, or aspartame
- Severe allergies to eggs, wheat, tree nuts, fish, crustaceans, shellfish products (Accelerade, the CHO-P supplement, is made in a facility that processed these products)
- Refusal to consume any of the supplements, and/or extreme dislike of the supplements
- Refusal to complete the specified distance of the time trials
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Order 1
Supplement order for each time trial run, 1-4 respectively: CHO, CHO-P, CHO-CHO, PLA
|
The CHO supplement will be administered during trial 1.
The CHO-P will be administered during trial 2. The CHO-CHO supplement will be administered during trial 3. The PLA supplement will be administered during trial 4.
This is the order of supplement administration for subjects randomly assigned to this order group.
|
Active Comparator: Order 2
Supplement order for each time trial run, 1-4 respectively: CHO-P, CHO-CHO, PLA, CHO
|
The CHO-P supplement will be administered during trial 1.
The CHO-CHO will be administered during trial 2. The PLA supplement will be administered during trial 3. The CHO supplement will be administered during trial 4.
This is the order of supplement administration for subjects randomly assigned to this order group.
|
Active Comparator: Order 3
Supplement order for each time trial run, 1-4 respectively: CHO-CHO, PLA, CHO, CHO-P
|
The CHO-CHO supplement will be administered during trial 1.
The PLA will be administered during trial 2. The CHO supplement will be administered during trial 3. The CHO-P supplement will be administered during trial 4.
This is the order of supplement administration for subjects randomly assigned to this order group.
|
Active Comparator: Order 4
Supplement order for each time trial run, 1-4 respectively: PLA, CHO, CHO-P, CHO-CHO
|
The PLA supplement will be administered during trial 1.
The CHO will be administered during trial 2. The CHO-P supplement will be administered during trial 3. The CHO-CHO supplement will be administered during trial 4.
This is the order of supplement administration for subjects randomly assigned to this order group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time it takes to complete each 12-mile time trial run
Time Frame: 4 days
|
4 days
|
Time it takes to complete the 1.6 mile maximal effort at the end of the 12 mile run.
Time Frame: 4 days
|
4 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Heart Rate at the beginning of each time trial, start of the maximal effort, end of the run.
Time Frame: 4 days
|
4 days
|
Rating of perceived exertion through out the duration of the 12 mile time trial run.
Time Frame: 4 days
|
4 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Hollie A Raynor, PhD, University of Tennessee, Knoxville
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Primary Completion (Actual)
April 1, 2010
Study Completion (Actual)
April 1, 2010
Study Registration Dates
First Submitted
September 3, 2009
First Submitted That Met QC Criteria
September 3, 2009
First Posted (Estimate)
September 4, 2009
Study Record Updates
Last Update Posted (Actual)
April 5, 2018
Last Update Submitted That Met QC Criteria
April 3, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Prednisolone
- Cyclophosphamide
- Prednisone
- Doxorubicin
- Vincristine
Other Study ID Numbers
- University of TN IRB 7959-B
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Supplementation During Endurance Performance
-
Texas Christian UniversityCompletedEndurance Cycling PerformanceUnited States
-
University of ExeterVDF FutureCeuticals Inc.CompletedCaffeine and Endurance PerformanceUnited Kingdom
-
University of ExeterVDF FutureCeuticals Inc.CompletedCaffine and Endurance PerformanceUnited Kingdom
-
Universidade Federal de Santa CatarinaCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.CompletedEndurance Performance | Sports Nutritional Sciences | Sports PerformanceBrazil
-
Lindenwood UniversityCompletedExercise Performance | Gastrointestinal Complication | Aerobic EnduranceUnited States
-
University of BaselCompletedMuscle Strength | Endurance Performance | Reaction TimeSwitzerland
-
University of AberdeenCompletedDietary Supplementation During ExerciseUnited Kingdom
-
Ågot AakraUniversity of Oslo; Norwegian School of Sport Sciences; Norwegian Olympic Sports...UnknownAthletes | Endurance Performance | Microbiota | Iron | Hemoglobin | Intestinal HealthNorway
-
University of Electronic Science and Technology...CompletedOxytocin Effect on Memory Performance During Phase 1 | Oxytocin Effect on Memory Performance During Phase 2 | Oxytocin Effect on Memory Performance During Phase 3 | Oxytocin Effect on Memory Performance During Phase 4China
-
Rajavithi HospitalCompletedPregnancy Outcome Among Vitamin D Supplementation During PregnancyThailand
Clinical Trials on CHO, CHO-P, CHO-CHO, PLA
-
Erica GoldsteinCompletedDietary SupplementationsUnited States
-
Wageningen UniversityRecruiting
-
Per Bendix JeppesenFuture Food InnovationCompletedAthletic PerformanceDenmark
-
University of AarhusInnovation Fund DenmarkRecruitingAthletic PerformanceDenmark
-
Abbott NutritionNot yet recruitingDiabetes type2
-
Federal University of Mato GrossoUnivag Centro UniversitárioRecruitingInsulin Resistance | Ketosis | Acute-Phase ResponseBrazil
-
Heart and Diabetes Center North-Rhine WestfaliaCompleted
-
Hospital Arnau de VilanovaCompletedGestational Diabetes Mellitus (GDM)Spain